Ethylamine derivatives
    2.
    发明授权
    Ethylamine derivatives 失效
    乙胺衍生物

    公开(公告)号:US06720433B2

    公开(公告)日:2004-04-13

    申请号:US10356558

    申请日:2003-02-03

    IPC分类号: C07D30738

    摘要: Ethylamine derivatives that function as a motilin receptor antagonist and are useful as medicines are represented by the general formula (1): wherein R1 represents a phenyl group or the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents an alkyl group and the like, R7 represents a hydrogen atom and the like and R8 represents a heterocyclic ring and the like; or a hydrate or pharmaceutically acceptable salt thereof.

    摘要翻译: 作为胃动素受体拮抗剂起作用并用作药物的乙胺衍生物由通式(1)表示:其中R1表示苯基等,R2表示氢原子等,R3表示氢原子, R 4表示氢原子等,R 5表示烷基等,R 7表示氢原子等,R 8表示杂环等。 或其水合物或药学上可接受的盐。

    Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
    3.
    发明授权
    Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes 失效
    葡萄糖醇衍生物,其前药及其盐,以及含有糖尿病的治疗剂

    公开(公告)号:US07943748B2

    公开(公告)日:2011-05-17

    申请号:US11658765

    申请日:2005-07-27

    IPC分类号: C07H1/00 A01N43/04 A61K31/70

    CPC分类号: C07D409/10

    摘要: The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

    摘要翻译: 本发明提供了具有降低血糖水平并且具有药物所需的优选性能如持久药物活性的功能的葡糖醇衍生物; 以及用于预防或治疗高血糖疾病如糖尿病,糖尿病并发症和肥胖症的药物组合物。 该衍生物是由式(I)表示的化合物:其中m是选自1-3的整数; R1至R4各自独立地为任选取代的烷基等; Ar1是任选取代的萘基; 和A是任选取代的杂芳基,该化合物的前药或其药学上可接受的盐。 还提供了含有化合物的药物,药物组合物等。

    Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
    4.
    发明申请
    Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes 有权
    新型环己烷衍生物,其前体药物及其盐,以及含有糖尿病的治疗剂

    公开(公告)号:US20080318874A1

    公开(公告)日:2008-12-25

    申请号:US11658400

    申请日:2005-07-26

    摘要: A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

    摘要翻译: 具有降低血糖水平并且具有药物所需的优选性能的持久性药物活性,代谢稳定性和安全性的环己烷衍生物; 以及用于预防或治疗高血糖疾病(例如糖尿病,例如胰岛素依赖性糖尿病(1型糖尿病)或非胰岛素依赖性糖尿病(2型糖尿病)),糖尿病并发症和肥胖症的药物组合物 。 该衍生物是由式(I)表示的化合物:其中A是-O-,-CH2-或-NH-; n是选自0和1之间的整数; R6和R7各自独立地是氢或C1- 6烷基; m是选自1-3中的整数; Q选自下式Q1至Q5; Ar1​​是任选取代的亚芳基或任选取代的亚杂芳基,条件是杂亚芳基可以键合到芳族碳环或芳族杂环以形成 稠合环; Ar 2是任选取代的芳基或任选取代的杂芳基),化合物的前药或其药学上可接受的盐。 还提供含有化合物的药物,药物组合物等。

    Cyclic motilin receptor antagonists
    5.
    发明授权
    Cyclic motilin receptor antagonists 失效
    循环胃动素受体拮抗剂

    公开(公告)号:US07018981B2

    公开(公告)日:2006-03-28

    申请号:US10362574

    申请日:2001-08-23

    IPC分类号: A61K38/12 C07K7/64

    摘要: The present invention aims to provide cyclic peptide derivatives having motilin receptor antagonist activity and are useful as pharmaceuticals. The present invention provides compounds of general formula (1): wherein R1 represents an optionally substituted phenyl group or the like; R2 represents an amino group or the like; R3 to R6 represent a hydrogen atom, a methyl group or the like; R7 represents a hydrogen atom or the like; V to Z represent a carbonyl group or a methylene group; m represents an integer of 0–2; and n represents an integer of 0–3; or a hydrate or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明旨在提供具有胃动素受体拮抗剂活性的环肽衍生物,并且可用作药物。 本发明提供通式(1)的化合物:其中R 1表示任选取代的苯基等; R 2表示氨基等; R 3至R 6表示氢原子,甲基等; R 7表示氢原子等; V至Z表示羰基或亚甲基; m表示0-2的整数; n表示0〜3的整数。 或其水合物或其药学上可接受的盐。

    Ethylamine derivatives
    6.
    发明授权
    Ethylamine derivatives 失效
    乙胺衍生物

    公开(公告)号:US06586630B1

    公开(公告)日:2003-07-01

    申请号:US09787674

    申请日:2001-03-21

    IPC分类号: C07C23305

    摘要: The object of the present invention is to provide ethylamine derivatives that function as a motilin receptor antagonist and that are useful as medicines. The invention provides compounds represented by the general formula (1): wherein R1 represents a phenyl group or the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents an alkyl group and the like, R7 represents a hydrogen atom and the like and R8 represents a heterocyclic ring and the like; or a hydrate or pharmaceutically acceptable salt thereof and a medicine which comprises the above compound or a hydrate or pharmaceutically acceptable salt thereof as an active ingredient.

    摘要翻译: 本发明的目的是提供作为胃动素受体拮抗剂起作用的乙胺衍生物,作为药物有用。本发明提供由通式(1)表示的化合物:其中,R1表示苯基等,R2表示 氢原子等,R 3表示氢原子等,R 4表示氢原子等,R 5表示烷基等,R 7表示氢原子等,R 8表示杂环等 ; 或其水合物或药学上可接受的盐和包含上述化合物或其水合物或药学上可接受的盐作为活性成分的药物。

    Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes
    8.
    发明申请
    Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes 失效
    新型葡萄糖醇衍生物,其药物及其盐,以及含有糖尿病的治疗剂

    公开(公告)号:US20080319047A1

    公开(公告)日:2008-12-25

    申请号:US11658765

    申请日:2005-07-27

    CPC分类号: C07D409/10

    摘要: The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

    摘要翻译: 本发明提供了具有降低血糖水平并且具有药物所需的优选性能如持久药物活性的功能的葡糖醇衍生物; 以及用于预防或治疗高血糖疾病如糖尿病,糖尿病并发症和肥胖症的药物组合物。 该衍生物是由式(I)表示的化合物:其中m是选自1-3的整数; R1至R4各自独立地为任选取代的烷基等; Ar1是任选取代的萘基; 和A是任选取代的杂芳基,该化合物的前药或其药学上可接受的盐。 还提供了含有化合物的药物,药物组合物等。

    TONER CARTRIDGE
    10.
    发明申请

    公开(公告)号:US20130034371A1

    公开(公告)日:2013-02-07

    申请号:US13650620

    申请日:2012-10-12

    申请人: Tsutomu Sato

    发明人: Tsutomu Sato

    IPC分类号: G03G15/08

    摘要: A toner cartridge comprises a toner container which contains toner, a driving member which rotationally drives a conveying member, an agitating member which agitates a toner in the toner container while being rotated, a driven member which rotates in association with the driving member which is for rotationally driving the agitating member, and a rotational body which rotates according to rotation of the driven member, has a plurality of slits in rotational circumference for identifying a type of the toner cartridge, and has 1/K or more of the slits when a ratio of a rotational speed R1 (rad/s) of the driving member and a rotational speed R2 (rad/s) of the driven member is K=R2/R1.